NEW YORK (GenomeWeb) – Guardant Health today announced the Guardant360 assay has been approved by New York State's Clinical Laboratory Evaluation Program.

The assay is the first liquid biopsy permitted by the program, which Guardant said is one of the most demanding lab certification programs in the country, and the approval means Guardant360 can be offered in all 50 states.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.